CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0369 (clinicaltrials.gov NCT No: NCT01380756)
Title:A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Myeloid Leukemia or AML
Principal Investigator:Hagop Kantarjian
Treatment Agent:AMG 900
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of AMG 900 and the best dosing schedule that can be given to patients with
AML. The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:AMG 900
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Amgen, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults